Search

Your search keyword '"Lindberg, Henriette"' showing total 196 results

Search Constraints

Start Over You searched for: Author "Lindberg, Henriette" Remove constraint Author: "Lindberg, Henriette"
196 results on '"Lindberg, Henriette"'

Search Results

2. Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial

3. Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial

5. Characteristics of Patients in SPCG-15—A Randomized Trial Comparing Radical Prostatectomy with Primary Radiotherapy plus Androgen Deprivation Therapy in Men with Locally Advanced Prostate Cancer

10. Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial

11. Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial

15. Rucaparib or Physician’s Choice in Metastatic Prostate Cancer

16. The iBLAD study:patient-reported outcomes in bladder cancer during oncological treatment: a multicenter national randomized controlled trial

17. Randomised phase II trial of stereotactic body radiotherapy in combination with checkpoint inhibitors in metastatic castration-resistant prostate cancer (CheckPRO):a study protocol

19. Randomised phase II trial of stereotactic body radiotherapy in combination withcheckpoint inhibitors in metastatic castration-resistantprostate cancer (CheckPRO): a study protocol

23. Fatigue, health-related quality-of-life and metabolic changes in men treated with enzalutamide or abiraterone acetate plus prednisone for metastatic castration-resistant prostate cancer: A randomised clinical trial (HEAT)

25. MP48-05 CHANGES IN PITUITARY–GONADAL HORMONES AFTER ENZALUTAMIDE OR ABIRATERONE PLUS PREDNISONE IN MEN WITH CASTRATION-RESISTANT PROSTATE CANCER (HEAT): RESULTS FROM A RANDOMISED CLINICAL TRIAL

26. Muscle mass and physical function in patients with bladder cancer—Data from a prematurely terminated prospective cohort study

27. Fatigue, health-related quality-of-life and metabolic changes in men treated with enzalutamide or abiraterone acetate plus prednisone for metastatic castration-resistant prostate cancer:A randomised clinical trial (HEAT)

28. Reasons for lack of treatment in patients with locally advanced, unresectable or metastatic urothelial carcinoma

29. Implications for Efficacy and Safety of Total Dose and Dose-Intensity of Neoadjuvant Gemcitabine-Cisplatin in Muscle-Invasive Bladder Cancer:Three-Week Versus Four-Week Regimen

30. Online adaptive radiotherapy of urinary bladder cancer with full re-optimization to the anatomy of the day:initial experience and dosimetric benefits

31. Implications for Efficacy and Safety of Total Dose and Dose-Intensity of Neoadjuvant Gemcitabine-Cisplatin in Muscle-Invasive Bladder Cancer: Three-Week Versus Four-Week Regimen

32. A phase I/II study of acute and late physician assessed and patient-reported morbidity following whole pelvic radiation in high-risk prostate cancer patients

35. A phase I/II study of acute and late physician assessed and patient-reported morbidity following whole pelvic radiation in high-risk prostate cancer patients

37. Circulating Forms of Urokinase-Type Plasminogen Activator Receptor in Plasma Can Predict Recurrence and Survival in Patients with Urothelial Carcinoma of the Bladder

38. Patient-reported outcomes, health-related quality of life, and clinical outcomes for urothelial cancer patients receiving chemo-or immunotherapy:A real-life experience

39. Quality of life in men with metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone:a systematic review and meta-analysis

40. Real-world Treatment Patterns and Overall Survival in Locally Advanced and Metastatic Urothelial Tract Cancer Patients Treated with Chemotherapy in Denmark in the Preimmunotherapy Era:A Nationwide, Population-based Study

41. Circulating forms of urokinase-type plasminogen activator receptor in plasma can predict recurrence and survival in patients with urothelial carcinoma of the bladder

43. Timing of radiotherapy after radical prostatectomy (RADICALS-RT):a randomised, controlled phase 3 trial

44. Electronic reporting of patient-reported outcomes in a fragile and comorbid population during cancer therapy - A feasibility study

45. Patient reported symptoms associated with quality of life during chemo- or immunotherapy for bladder cancer patients with advanced disease

46. Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial

50. Fatigue, quality of life and metabolic changes in men treated with first-line enzalutamide versus abiraterone plus prednisolone for metastatic castration-resistant prostate cancer (HEAT):A randomised trial protocol

Catalog

Books, media, physical & digital resources